Actively Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Led by BeiGene · Updated on 2026-03-12
87
Participants Needed
26
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
CONDITIONS
Official Title
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide signed and dated informed consent before any study procedures
- Age 18 years or older or legal age of consent where study takes place
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors previously treated
- At least 1 measurable or nonmeasurable lesion by RECIST v1.1 (Phase 1a Part A); at least 1 measurable lesion by RECIST v1.1 (Phase 1a Part B and Phase 1b)
- Adequate organ function
You will not qualify if you...
- Prior severe allergic reactions or hypersensitivity to BG-T187 or other monoclonal antibodies
- Spinal cord compression, active leptomeningeal disease, or uncontrolled/untreated brain metastasis
- Any cancer diagnosed within 3 years before first dose except study cancer or locally recurring cancer treated with curative intent
- History of interstitial lung disease or noninfectious pneumonitis requiring steroids or immune suppressants within 2 years, current ILD/noninfectious pneumonitis, or suspected ILD/noninfectious pneumonitis not ruled out by imaging
- Uncontrollable pleural, pericardial effusion, or ascites needing frequent drainage (recurrence less than 14 days after intervention)
- Active hepatitis C
- Infection requiring systemic antibacterial, antifungal, or antiviral treatment within 14 days before first dose
- Other protocol-defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 26 locations
1
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601-1915
Actively Recruiting
2
The University of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Actively Recruiting
3
Next Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
4
Washington University, St Louis, Division of Oncology
Madison, Wisconsin, United States, 53708-8056
Actively Recruiting
5
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia, NSW 2148
Actively Recruiting
6
Macquarie University
North Ryde, New South Wales, Australia, NSW 2109
Actively Recruiting
7
Cabrini Hospital Malvern
Malvern East, Victoria, Australia, VIC 3144
Actively Recruiting
8
Linear Clinical Research
Nedlands, Western Australia, Australia, WA 6009
Actively Recruiting
9
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
10
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
11
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
12
The Sixth Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, China, 510655
Actively Recruiting
13
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Actively Recruiting
14
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
15
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
16
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
17
Linyi Peoples Hospital
Linyi, Shandong, China, 276000
Actively Recruiting
18
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
19
The First Affiliated Hospital, Zhejiang University School of Medicinezhijiang Branch
Hangzhou, Zhejiang, China, 310024
Actively Recruiting
20
The Catholic University of Korea, St Vincents Hospital
PaldalGu SuwonSi, Gyeonggi-do, South Korea, 16247
Actively Recruiting
21
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
22
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea, 06351
Actively Recruiting
23
The Catholic University of Korea, Seoul St Marys Hospital
SeochoGu, Seoul Teugbyeolsi, South Korea, 06591
Actively Recruiting
24
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea, 03722
Actively Recruiting
25
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea, 03080
Actively Recruiting
26
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea, 05505
Actively Recruiting
Research Team
S
Study Director
CONTACT
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here